Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38

Ming Cheng Chen, Nien Hung Lee, Hsi Hsien Hsu, Tsung Jung Ho, Chuan Chou Tu, Ray Jade Chen, Yueh Min Lin, Vijaya Padma Viswanadha, Wei Wen Kuo, Chih Yang Huang

研究成果: 雜誌貢獻文章同行評審

34 引文 斯高帕斯(Scopus)

摘要

Clinically used chemotherapeutics can effectively eliminate most tumor cells. However, they cause unwanted side effects and result in chemoresistance. To overcome such problems, phytochemicals are now used to treat cancers by means of targeted therapy. Thymoquinone (TQ) is used to treat different cancers (including colon cancer) and is an NF-κB inhibitor. Irinotecan resistant (CPT-11-R) LoVo colon cancer cell line was previous constructed by step-wise CPT-11 challenges to un-treated parental LoVo cells and expresses EGFR/IKKα/β/NF-κB pathway. TQ resulted in reduced total and phosphorylation of IKKα/β and NF-κB and decreased metastasis in CPT-11-R cells. TQ not only reduced activity of ERK1/2 and PI3K but also activated JNK and p38. Furthermore, TQ was also found to suppress metastasis through activation of JNK and p38. Therefore, TQ suppressed metastasis through NF-κB inhibition and activation of JNK and p38 in CPT-11-R LoVo colon cancer cells.
原文英語
頁(從 - 到)669-678
頁數10
期刊Environmental Toxicology
32
發行號2
DOIs
出版狀態已發佈 - 2月 1 2017

ASJC Scopus subject areas

  • 健康、毒理學和誘變
  • 毒理學
  • 管理、監督、政策法律

指紋

深入研究「Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38」主題。共同形成了獨特的指紋。

引用此